Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $213.08

Icon Plc (NASDAQ:ICLR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fifteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $213.08.

A number of equities research analysts have issued reports on ICLR shares. Mizuho reduced their target price on shares of Icon from $200.00 to $173.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. JPMorgan Chase & Co. lowered shares of Icon from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $265.00 to $150.00 in a report on Tuesday, April 29th. TD Cowen lowered shares of Icon from a "buy" rating to a "hold" rating and reduced their price objective for the company from $254.00 to $157.00 in a report on Monday, April 14th. Citigroup reduced their price objective on shares of Icon from $290.00 to $215.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Finally, Robert W. Baird reduced their price objective on shares of Icon from $192.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd.

Institutional Investors Weigh In On Icon

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Private Trust Co. NA raised its stake in Icon by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock worth $52,000 after acquiring an additional 82 shares in the last quarter. Transcend Capital Advisors LLC raised its stake in Icon by 7.6% during the 1st quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company's stock worth $205,000 after acquiring an additional 83 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Icon by 22.8% during the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock worth $99,000 after acquiring an additional 110 shares in the last quarter. Pinnacle Wealth Planning Services Inc. raised its stake in Icon by 8.7% during the 1st quarter. Pinnacle Wealth Planning Services Inc. now owns 1,657 shares of the medical research company's stock worth $290,000 after acquiring an additional 132 shares in the last quarter. Finally, Horizon Investments LLC raised its stake in Icon by 23.7% during the 1st quarter. Horizon Investments LLC now owns 808 shares of the medical research company's stock worth $141,000 after acquiring an additional 155 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Trading Down 1.5%

Shares of NASDAQ:ICLR traded down $2.19 during mid-day trading on Thursday, reaching $144.56. 1,212,929 shares of the company were exchanged, compared to its average volume of 1,095,714. The firm has a market cap of $11.67 billion, a price-to-earnings ratio of 15.75, a P/E/G ratio of 1.77 and a beta of 1.15. Icon has a 1 year low of $125.10 and a 1 year high of $347.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.27 and a quick ratio of 1.27. The firm's 50-day simple moving average is $139.13 and its 200 day simple moving average is $171.71.

Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.17 by $0.02. The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.03 billion. Icon had a net margin of 9.25% and a return on equity of 11.46%. The firm's quarterly revenue was down 4.3% on a year-over-year basis. During the same period in the prior year, the business earned $3.47 EPS. Equities research analysts forecast that Icon will post 13.38 EPS for the current year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.